Compare GE Vernova Inc (GEV) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Recursion Pharmaceuticals Inc — how do they compare? GE Vernova Inc trades at $1,000 (market cap $266.16B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: GE Vernova Inc is far larger — about 124.4× Recursion Pharmaceuticals Inc's market cap, and GE Vernova Inc pays a 0.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GEV | RXRX | |
|---|---|---|
Market Cap | $266.16B | $2.14B |
Volume | 2,324,165 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $1.17K | $6.79 |
52-Week Low | $547.96 | $2.84 |
Typical Hold Time | 36 Days | 22 Days |
Enterprise Value | $255.83B | $1.66B |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $986.62, down 1.05% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical momentum with support at $973 and resistance at $1,026. Recent Q1 2026 earnings beat expectations with EPS of $17.44 versus $1.95 expected, while Q2 2026 missed estimates. The company secured the first US construction permit for its BWRX-300 small modular reactor, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with projected revenue growth to $41.4B in 2026 and net profit margin expanding to 23.03%. Key risks include valuation concerns with P/E of 28.65 and EV/EBITDA of 85.22, plus execution challenges in scaling nuclear projects. The stock offers exposure to AI infrastructure growth but requires monitoring of margin expansion and backlog conversion.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
